Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Comparing the COVID-19 Vaccines: How Are They Different? > News > Yale Medicine
Why and When to Get a Bivalent Covid-19 Booster | Johns Hopkins | Bloomberg School of Public Health
Evidence to recommendation Framework: Bivalent COVID-19 vaccine booster doses
CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines | The Scientist Magazine®
Bivalent COVID-19 mRNA Booster Effective - Southern Iowa Mental Health Center
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
COVID-19 bivalent booster effectiveness in people with and without immune dysfunction L
COVID-19 Bivalent Boosters | Johns Hopkins | Bloomberg School of Public Health
Durability of Bivalent Boosters against Omicron Subvariants | NEJM
Let's discuss COVID-19 Bivalent Booster Effectiveness - ICAP
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
Effectiveness of Bivalent Boosters against Severe Omicron Infection | NEJM
Studies show real-world usefulness of bivalent COVID boosters | CIDRAP
CDC reports on bivalent COVID-19 vaccine, Paxlovid effectiveness | AHA News
Bivalent mRNA booster effective, 'essential' for older adults
Evaluating SARS-CoV-2 bivalent booster vaccine against severe COVID-19 outcomes
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
A quick update on the bivalent boosters - by Eric Topol
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
New Omicron-specific vaccines offer similar protection to existing boosters
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
